Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × HER2 Overexpression × trastuzumab deruxtecan × Clear all

Status

Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 2 Neoplasms 2 Breast Cancer With Brain Metastasis 2 Recurrence 1 Ovarian Neoplasms 1 HER2 Overexpression 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Advanced Solid Tumor 1

Interventions

trastuzumab deruxtecan 1 Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡